title: Invasive pulmonary fungal infection in hematologic patients: is resection effective?
abstract: BACKGROUND
  Invasive pulmonary aspergillosis carries a high mortality in neutropenic patients. Descriptive reports have shown early surgery to be feasible with acceptably low morbidity. The possible benefit of surgery has not been investigated in comparative studies.
  
  
  METHODS
  In a retrospective cohort study encompassing a 15-year period, 54 (8%) of 697 consecutive patients with severe hematological disease required treatment for localized invasive pulmonary aspergillosis. Patients treated by antifungal drugs (medical group, n = 24) were compared to patients treated with additional early lung resection (surgical group, n = 30). Outcomes analysed were fungal progression and survival.
  
  
  RESULTS
  Fungal progression at six months was 17% (95% CI 3-31) in the surgical group and 52% (95% CI 34-73) in the medical group (P = 0.005). Survival at six months was 70% (95% CI 53-87) in surgically and 42% (95% CI 24-62) in medically treated patients (P = 0.009). Adjusting for differences in WHO performance score (worse in the medical group) and duration of neutropenia (longer in the surgical group) in a multivariate analysis, a difference in relative risk of death (0.26; 95% CI 0.08-0.88; P = 0.03) remained in favor of surgery.
  
  
  CONCLUSIONS
  In this retrospective study surgical intervention to treat invasive pulmonary fungal disease appeared to have a beneficial effect on the impact of disease control and survival. Differences in baseline characteristics of the two patient groups calls for cautious interpretation. A prospective randomized trial seems warranted.
authors.affiliation: Division of Cardio-Thoracic Surgery, Department of Surgery, University Hospital, Basel, Switzerland. jhabicht@uhbs.ch
authors.forename: J M
authors.initials: JM
authors.lastname: Habicht
authors.forename: P
authors.initials: P
authors.lastname: Matt
authors.forename: J R
authors.initials: JR
authors.lastname: Passweg
authors.forename: F
authors.initials: F
authors.lastname: Reichenberger
authors.forename: A
authors.initials: A
authors.lastname: Gratwohl
authors.forename: H R
authors.initials: HR
authors.lastname: Zerkowski
authors.forename: M
authors.initials: M
authors.lastname: Tamm
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage; D001228:Aspergillosis / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008172:Lung Diseases, Fungal / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000150:complications / Q000382:microbiology; D011013:Pneumonectomy / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents